- Home
- NDLS vs CELU Comparison
NDLS vs CELU Comparison
Compare NDLS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- CELU
- Stock Information
- Founded
- NDLS 1995
- CELU 2016
- Country
- NDLS United States
- CELU United States
- Employees
- NDLS N/A
- CELU N/A
- Industry
- NDLS Restaurants
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- CELU Health Care
- Exchange
- NDLS Nasdaq
- CELU Nasdaq
- Market Cap
- NDLS 35.4M
- CELU 42.2M
- IPO Year
- NDLS 2013
- CELU N/A
- Fundamental
- Price
- NDLS $0.72
- CELU $1.94
- Analyst Decision
- NDLS Strong Buy
- CELU
- Analyst Count
- NDLS 2
- CELU 0
- Target Price
- NDLS $3.00
- CELU N/A
- AVG Volume (30 Days)
- NDLS 198.4K
- CELU 73.1K
- Earning Date
- NDLS 08-06-2025
- CELU 05-08-2025
- Dividend Yield
- NDLS N/A
- CELU N/A
- EPS Growth
- NDLS N/A
- CELU N/A
- EPS
- NDLS N/A
- CELU N/A
- Revenue
- NDLS $495,670,000.00
- CELU $54,220,000.00
- Revenue This Year
- NDLS $5.37
- CELU $23.29
- Revenue Next Year
- NDLS $0.68
- CELU N/A
- P/E Ratio
- NDLS N/A
- CELU N/A
- Revenue Growth
- NDLS N/A
- CELU 138.11
- 52 Week Low
- NDLS $0.55
- CELU $1.00
- 52 Week High
- NDLS $1.83
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- NDLS 36.25
- CELU 49.61
- Support Level
- NDLS $0.76
- CELU $1.80
- Resistance Level
- NDLS $0.82
- CELU $2.17
- Average True Range (ATR)
- NDLS 0.06
- CELU 0.18
- MACD
- NDLS -0.00
- CELU -0.01
- Stochastic Oscillator
- NDLS 4.80
- CELU 42.48
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.